期刊
NUCLEIC ACIDS RESEARCH
卷 49, 期 15, 页码 8556-8572出版社
OXFORD UNIV PRESS
DOI: 10.1093/nar/gkab626
关键词
-
资金
- National Key R&D Program of China [2018YFC1005004]
- Major Special Projects of Basic Research of Shanghai Science and Technology Commission [18JC1411101]
- National Natural Science Foundation of China [22021003, 31872814, 31671308]
- Shanghai Science and Technology Commission [18JC1411104, 20Y11914100]
- Strategic Priority Research Program of the Chinese Academy of Sciences [XDPB2004]
- Jinshan Hospital of Fudan University
Dysfunction of Tumour Suppressor Genes (TSGs) is common in carcinogenesis, with low expression of miRNA potentially reducing TSG activity through enhancer regulation. In breast cancer, downregulation of GPER1 and miR-339 is observed, with mechanistic investigations revealing the role of miR-339 in upregulating GPER1 expression through enhancer switching. This highlights a potential alternative strategy for breast cancer treatment through reactivation of TSGs by enhancer manipulation.
Dysfunction of Tumour Suppressor Genes (TSGs) is a common feature in carcinogenesis. Epigenetic abnormalities including DNA hypermethylation or aberrant histone modifications in promoter regions have been described for interpreting TSG inactivation. However, in many instances, how TSGs are silenced in tumours are largely unknown. Given that miRNA with low expression in tumours is another recognized signature, we hypothesize that low expression of miRNA may reduce the activity of TSG related enhancers and further lead to inactivation of TSG during cancer development. Here, we reported that low expression of miRNA in cancer as a recognized signature leads to loss of function of TSGs in breast cancer. In 157 paired breast cancer and adjacent normal samples, tumour suppressor gene GPER1 and miR-339 are both downregulated in Luminal A/B and Triple Negative Breast Cancer subtypes. Mechanistic investigations revealed that miR-339 upregulates GPER1 expression in breast cancer cells by switching on the GPER1 enhancer, which can be blocked by enhancer deletion through the CRISPR/Cas9 system. Collectively, our findings reveal novel mechanistic insights into TSG dysfunction in cancer development, and provide evidence that reactivation of TSG by enhancer switching may be a promising alternative strategy for clinical breast cancer treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据